{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FGFR2+Gene+Mutation", "query": { "condition": "FGFR2 Gene Mutation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FGFR2+Gene+Mutation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:26:49.073Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02150967", "title": "A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cholangiocarcinoma", "FGFR2 Gene Mutation" ], "interventions": [ { "name": "BGJ398 (infigratinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2014-07-23", "completion_date": "2022-02-07", "has_results": true, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02150967" }, { "nct_id": "NCT02706691", "title": "BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "FGFR Gene Amplification", "FGFR1 Gene Amplification", "FGFR2 Gene Amplification", "FGFR2 Gene Mutation", "FGFR3 Gene Mutation", "Head and Neck Squamous Cell Carcinoma", "Human Papillomavirus Infection", "Recurrent Head and Neck Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "BGJ398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-06-01", "completion_date": "2019-02-11", "has_results": true, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706691" }, { "nct_id": "NCT03230318", "title": "Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intrahepatic Cholangiocarcinoma", "Combined Hepatocellular and Cholangiocarcinoma" ], "interventions": [ { "name": "derazantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Basilea Pharmaceutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2017-09-28", "completion_date": "2022-10-25", "has_results": true, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03230318" }, { "nct_id": "NCT01752920", "title": "Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Derazantinib low dose range", "type": "DRUG" }, { "name": "Derazantinib middle dose range", "type": "DRUG" }, { "name": "Derazantinib high dose range", "type": "DRUG" }, { "name": "Derazantinib at recommended phase 2 dose (RP2D)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Basilea Pharmaceutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2012-12-10", "completion_date": "2018-08-28", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01752920" }, { "nct_id": "NCT06160752", "title": "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Cholangiocarcinoma", "Intrahepatic Cholangiocarcinoma", "Solid Tumor", "Metastatic Cholangiocarcinoma" ], "interventions": [ { "name": "Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" }, { "name": "Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-11-22", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06160752" }, { "nct_id": "NCT02965378", "title": "Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "FGFR1 Gene Amplification", "FGFR1 Gene Mutation", "FGFR2 Gene Amplification", "FGFR2 Gene Mutation", "FGFR3 Gene Amplification", "FGFR3 Gene Mutation", "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "FGFR Inhibitor AZD4547", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 43, "start_date": "2014-10", "completion_date": "2019-10", "has_results": true, "last_update_posted_date": "2021-05-27", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 1083, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02965378" }, { "nct_id": "NCT02272998", "title": "Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "ponatinib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sameek Roychowdhury", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2015-02-24", "completion_date": "2022-11-17", "has_results": true, "last_update_posted_date": "2025-03-24", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Columbus, Ohio", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02272998" }, { "nct_id": "NCT01004224", "title": "A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3", "Squamous Lung Cancer With FGFR1 Amplification", "Bladder Cancer With FGFR3 Mutation or Fusion", "Advanced Solid Tumors With FGFR1 Amplication", "Advanced Solid Tumors With FGFR2 Amplication", "Advanced Solid Tumors With FGFR3 Mutation" ], "interventions": [ { "name": "BGJ398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2009-12-11", "completion_date": "2018-10-08", "has_results": false, "last_update_posted_date": "2019-10-04", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004224" }, { "nct_id": "NCT03773302", "title": "Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Cholangiocarcinoma", "FGFR2 Gene Mutation" ], "interventions": [ { "name": "BGJ398", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2019-12-27", "completion_date": "2023-03-02", "has_results": true, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 25, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 17 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03773302" }, { "nct_id": "NCT05222165", "title": "Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "CNS Tumor", "Recurrent WHO Grade II Glioma" ], "interventions": [ { "name": "Infigratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Healthcare SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-01", "completion_date": "2022-12-16", "has_results": false, "last_update_posted_date": "2023-02-23", "last_synced_at": "2026-05-21T22:26:49.073Z", "location_count": 6, "location_summary": "Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05222165" } ] }